David Martin, MD
Internal Medicine · Whiteville, NCNPI 1639131022
Payments from drug & device makers
Across 96 payments — averaging $26.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$560
- AbbVie$267
- Johnson & Johnson$216
- Novo Nordisk$175
- Abbott$148
- Amarin Pharma, Inc.$145
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,55799%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 11 | $560 |
| AbbVie(2 entities) | 9 | $267 |
| Johnson & Johnson | 2 | $216 |
| Novo Nordisk | 7 | $175 |
| Abbott | 8 | $148 |
| Amarin Pharma, Inc. | 1 | $145 |
| Boston Scientific | 1 | $100 |
| Phathom Pharmaceuticals, Inc. | 6 | $98 |
| Pfizer | 5 | $93 |
| Amgen | 6 | $87 |
| Lilly USA, LLC | 5 | $82 |
| Astellas Pharma US Inc | 4 | $80 |
| GSK | 5 | $75 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $65 |
| Ardelyx, Inc. | 4 | $63 |
| Xeris Pharmaceuticals, Inc. | 2 | $37 |
| Radius Health, Inc. | 2 | $34 |
| Exact Sciences | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
| Irhythm Technologies, Inc. | 1 | $23 |
| Forte Bio-pharma LLC | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Merck | 1 | $16 |
| Insulet Corporation | 1 | $16 |
| Viatris Specialty LLC | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
| Bayer | 1 | $14 |
| Intra-sana Laboratories | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,571 in reported general payments places this provider in the 80th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 14 | $451,245 |
| EliquisApixaban | 512 | $235,368 |
| LinzessLinaclotide | 202 | $120,191 |
| JardianceEmpagliflozin | 94 | $78,292 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 115 | $77,811 |
| OzempicSemaglutide | 72 | $68,584 |
| RybelsusSemaglutide | 64 | $59,463 |
| TrulicityDulaglutide | 53 | $57,317 |
| XareltoRivaroxaban | 103 | $53,797 |
| JanuviaSitagliptin Phosphate | 71 | $48,321 |
| MounjaroTirzepatide | 39 | $45,936 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 49 | $43,243 |
| FarxigaDapagliflozin Propanediol | 67 | $33,482 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 42 | $24,278 |
| MyrbetriqMirabegron | 62 | $22,831 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin, Abrysvo | $93 | $256,564582 claims |
| AbbVieLinzess, Restasis | $267 | $134,291216 claims |
| Novo NordiskOzempic, Rybelsus | $175 | $128,047136 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat, Tradjenta | $14 | $114,949175 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $82 | $103,25392 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $75 | $89,397133 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $560 | $87,316160 claims |
| MerckJanuvia, Janumet Xr | $16 | $72,599113 claims |
| Johnson & JohnsonXarelto | $216 | $53,797103 claims |
| Astellas Pharma US IncMyrbetriq | $80 | $22,83162 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Whiteville
- Manesh PatelDurham$27.2M
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- John RubinoRaleigh$13M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- Sylvia ShoffnerCary$7.1M
- Wayne HarperRaleigh$6.7M
- Joseph MoranStatesville$6.7M
- April SalamaDurham$6.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.